Indaptus Therapeutics Stock Performance

INDP Stock  USD 2.25  0.03  1.35%   
The company retains a Market Volatility (i.e., Beta) of -0.14, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Indaptus Therapeutics are expected to decrease at a much lower rate. During the bear market, Indaptus Therapeutics is likely to outperform the market. At this point, Indaptus Therapeutics has a negative expected return of -0.11%. Please make sure to check out Indaptus Therapeutics' value at risk, and the relationship between the jensen alpha and skewness , to decide if Indaptus Therapeutics performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Indaptus Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with latest sluggish performance, the Stock's fundamental indicators remain invariable and the latest agitation on Wall Street may also be a sign of long-running gains for the enterprise retail investors. ...more

Actual Historical Performance (%)

One Day Return
1.35
Five Day Return
3.69
Year To Date Return
27.84
Ten Year Return
(99.53)
All Time Return
(99.53)
Last Split Factor
1:4
Dividend Date
2020-10-30
Last Split Date
2021-07-27
1
Indaptus Surges on Upbeat Pre-Clinical Decoy Data - Yahoo Movies UK
04/17/2024
2
Acquisition by Hayes William B of 12500 shares of Indaptus Therapeutics at 1.82 subject to Rule 16b-3
04/18/2024
3
12 Health Care Stocks Moving In Thursdays After-Market Session - Aptevo Therapeutics , Alla - Benzinga
05/02/2024
4
INDP Stock Earnings Indaptus Therapeutics Misses EPS for Q1 2024
05/08/2024
5
Acquisition by Pomerantz Roger of 30000 shares of Indaptus Therapeutics at 1.82 subject to Rule 16b-3
05/10/2024
6
Indaptus Therapeutics to Present New Cohort Data Confirming Original Pulse-Prime Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Cli...
05/29/2024
7
AISES Names Navajo Transitional Energy Company a Top 50 Workplace for Indigenous STEM Professionals
05/30/2024
8
Indaptus reports positive Phase 1 trial results for cancer treatment
06/03/2024
9
12 Health Care Stocks Moving In Fridays Pre-Market Session - BioCardia , Adlai Nortye NASDAQ ... - Benzinga
06/07/2024
10
Indaptus Therapeutics to Present Positive Data on Lead Product Candidate, Decoy20, at STING TLR-Targeted Therapies Summit
06/11/2024
11
Fibromyalgia Market Report 2034 Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight
07/11/2024
Begin Period Cash Flow9.6 M
  

Indaptus Therapeutics Relative Risk vs. Return Landscape

If you would invest  262.00  in Indaptus Therapeutics on April 13, 2024 and sell it today you would lose (37.00) from holding Indaptus Therapeutics or give up 14.12% of portfolio value over 90 days. Indaptus Therapeutics is currently does not generate positive expected returns and assumes 5.2267% risk (volatility on return distribution) over the 90 days horizon. In different words, 46% of stocks are less volatile than Indaptus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Indaptus Therapeutics is expected to under-perform the market. In addition to that, the company is 9.08 times more volatile than its market benchmark. It trades about -0.02 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.17 per unit of volatility.

Indaptus Therapeutics Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Indaptus Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Indaptus Therapeutics, and traders can use it to determine the average amount a Indaptus Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.0217

Best PortfolioBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative ReturnsINDP

Estimated Market Risk

 5.23
  actual daily
46
54% of assets are more volatile

Expected Return

 -0.11
  actual daily
0
Most of other assets have higher returns

Risk-Adjusted Return

 -0.02
  actual daily
0
Most of other assets perform better
Based on monthly moving average Indaptus Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Indaptus Therapeutics by adding Indaptus Therapeutics to a well-diversified portfolio.

Indaptus Therapeutics Fundamentals Growth

Indaptus Stock prices reflect investors' perceptions of the future prospects and financial health of Indaptus Therapeutics, and Indaptus Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Indaptus Stock performance.

About Indaptus Therapeutics Performance

Assessing Indaptus Therapeutics' fundamental ratios provides investors with valuable insights into Indaptus Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Indaptus Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Return On Tangible Assets(1.03)(1.09)
Return On Capital Employed(1.35)(1.28)
Return On Assets(1.03)(1.09)
Return On Equity(1.28)(1.21)

Things to note about Indaptus Therapeutics performance evaluation

Checking the ongoing alerts about Indaptus Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Indaptus Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Indaptus Therapeutics generated a negative expected return over the last 90 days
Indaptus Therapeutics has high historical volatility and very poor performance
Net Loss for the year was (15.42 M) with profit before overhead, payroll, taxes, and interest of 0.
Indaptus Therapeutics currently holds about 33.01 M in cash with (13.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.0, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Indaptus Therapeutics has a frail financial position based on the latest SEC disclosures
Roughly 31.0% of the company shares are held by company insiders
Latest headline from kalkinemedia.com: Fibromyalgia Market Report 2034 Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight
Evaluating Indaptus Therapeutics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Indaptus Therapeutics' stock performance include:
  • Analyzing Indaptus Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Indaptus Therapeutics' stock is overvalued or undervalued compared to its peers.
  • Examining Indaptus Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Indaptus Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Indaptus Therapeutics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Indaptus Therapeutics' stock. These opinions can provide insight into Indaptus Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Indaptus Therapeutics' stock performance is not an exact science, and many factors can impact Indaptus Therapeutics' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for Indaptus Stock Analysis

When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.